Publications

Publications

Filter Results: (24) Arrow Down

Show Results For

McComb, Emily R.Remove McComb, Emily R. →

← Page 2 of 24 Results
  • March 2018 (Revised May 2018)
  • Case

Celgene

By: Malcolm Baker and Emily McComb
In February 2011, Adam Koppel, a managing director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm’s position in Celgene Corporation. News has emerged that raises potential safety concerns associated with... View Details
Keywords: Life Sciences; Biotechnology; Public Market Investing; Celgene; Revlimid; Hedge Fund; Growth Stocks; Valuation; Investment; Decision Choices and Conditions; Analysis; Biotechnology Industry
Related
  • March 2018 (Revised May 2018)
  • Supplement

Celgene (B)

By: Malcolm Baker and Emily McComb
Supplements the (A) case. View Details
Keywords: Life Sciences; Biotechnology; Public Market Investing; Celgene; Revlimid; Hedge Fund; Growth Stocks; Valuation; Investment; Decision Choices and Conditions; Analysis; Biotechnology Industry
Related
  • January 2018 (Revised January 2019)
  • Supplement

Capital Allocation at HCA

By: W. Carl Kester and Emily R. McComb
Related
  • January 2018 (Revised April 2021)
  • Case

Capital Allocation at HCA

By: W. Carl Kester and Emily R. McComb
In early 2017, HCA Holdings, an investor-owned hospital management company, faced a strategically important capital allocation decision. After the exit of its private equity sponsors in 2016, HCA had to determine how best to allocate its substantial annual free cash... View Details
Keywords: Capital Allocation; Cash Distribution Policy; Dividends; Share Repurchases; Growth Strategy And Execution; Growth Investing; Capital Expenditures; Debt Management; Debt Reduction; Debt Policy; Hospital Management; Investor-owned Hospital Chains; Capital Budgeting; Capital Structure; Cash Flow; Corporate Finance; Decision Choices and Conditions; Health Industry; United States
Related